Cyclic Nucleotide Phosphodiesterases: Properties, Activators, Inhibitors, Structure–Activity Relationships, and Possible Role in Drug Development
- 1 January 1975
- journal article
- research article
- Published by Elsevier in Journal of Pharmaceutical Sciences
- Vol. 64 (1) , 1-37
- https://doi.org/10.1002/jps.2600640106
Abstract
No abstract availableKeywords
This publication has 97 references indexed in Scilit:
- Relationship between the inhibition constant (KI) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reactionBiochemical Pharmacology, 1973
- Localization and correlation of catecholamine‐containing cells with adenyl cyclase and phosphodiesterase activities in the human fetal heartThe Anatomical Record, 1973
- Nicotinamide inhibition of 3′,5′- cyclic AMP phosphodiesterase in vitroBiochemical and Biophysical Research Communications, 1972
- Cyclic AMP phosphodiesterase interaction with its inhibitor of the slime mold, Dictyostelium discoideumBiochemical and Biophysical Research Communications, 1972
- Platelet aggregation IV. Platelet phosphodiesterase and its inhibition by vasodilatorsBiochemical and Biophysical Research Communications, 1971
- The metabolism of exogenous cyclic AMP at low concentrations by thymic lymphocytesBiochemical and Biophysical Research Communications, 1971
- Calcium dependent phosphodiesterase activity and its activating factor (PAF) from brainBiochemical and Biophysical Research Communications, 1970
- Cyclic 3′,5′-nucleotide phosphodiesteraseBiochemical and Biophysical Research Communications, 1970
- Effects of glucocorticoids and insulin on 3?,5?-AMP phosphodiesterase activity in adrenalectomized ratsDiabetologia, 1968
- Cyclic 3′, 5′-nucleotide phosphodiesterase: Pronounced stimulation by snake venomBiochemical and Biophysical Research Communications, 1967